HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and maintains $25 price target.
Reported Late Thursday Feb 9, BriaCell Therapeutics Corp. Announces Results Of Shareholder Meeting; Approval Of The Company’s New Omnibus Equity Incentive Plan
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to
BriaCell Therapeutics Granted U.S. Patent# 11559574: Whole-cell Cancer Vaccines And Methods For Selection Thereof
https://www.scribd.com/document/621627063/BCTX-Patent
BriaCell To Investigate Alleged Illegal Trading Of Public Securities
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announced today
BriaCell Announces End Of Phase II Meeting With FDA For Bria-IMT Combination In Advanced Metastatic Breast Cancer; FDA Has Agreed On Primary Endpoint
BriaCell has received agreement and positive feedback from its End of Phase II meeting with the FDA for lead clinical candidate, Bria-IMT™ in combination with a checkpoint inhibitor, in advanced metastatic breast
Earlier Reported, BriaCell CEO Discusses Clinical Results Of Its Breast Cancer Immunotherapy Treatment In An Audio Interview With SmallCapVoice.com
SmallCapVoice.com Inc. ("SCV") announces the availability of a new audio interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp.
BriaCell Announces Completion Of Phase I Portion Of Clinical Study In Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing
BriaCell has successfully completed its Phase I safety and tolerability evaluation of Bria-IMT™ in combination with Incyte's retifanlimab in advanced breast cancer.
The combination treatment showed a
Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday
Gainers
Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday.
BriaCell Enters Research Agreement To Identify Novel Targets For Cancer Treatment
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, today
Creatv Bio Announced LifeTracDx Liquid Biopsy Predicts Response to New Line of Therapy for Metastatic Breast Cancer, Including BriaCell’s Cancer Vaccine, within 30 Days; Data Presented at ASCO
Creatv Bio, Division of Creatv MicroTech, Inc., announced today the release of an abstract featuring the results of its LifeTracDx®blood test for predicting response of metastatic breast cancer (mBC) to new lines of therapy following a single cycle of therapy induction.